Jefferies analyst Brandon Couillard says near-term downside in shares of Dentsply Sirona "seems limited" after the company announced a "whole slew of negative headlines" when reporting Q2, including another guidance cut, a $1.2B impairment to Sirona, and a new restructuring program with few specifics. While "clearly frustrating" and "patience will be needed," there is reason for optimism heading into 2019, Couillard tells investors in a post-earnings research note. He lowered his price target for Dentsply Sirona to $46 from $58 and keeps a Buy rating on the shares.